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Abstract
Background: The shift from conventional two-dimensional (2D) to three-dimensional (3D)-
conformal target definition and dose-planning seems to have introduced volumetric as well as
geometric changes. The purpose of this study was to compare coverage of computed tomography
(CT)-based breast and boost planning target volumes (PTV), absolute volumes irradiated, and dose
delivered to the organs at risk with conventional 2D and 3D-conformal breast conserving
radiotherapy.
Methods: Twenty-five patients with left-sided breast cancer were subject of CT-guided target
definition and 3D-conformal dose-planning, and conventionally defined target volumes and
treatment plans were reconstructed on the planning CT. Accumulated dose-distributions were
calculated for the conventional and 3D-conformal dose-plans, taking into account a prescribed
dose of 50 Gy for the breast plans and 16 Gy for the boost plans.
Results: With conventional treatment plans, CT-based breast and boost PTVs received the
intended dose in 78% and 32% of the patients, respectively, and smaller volumes received the
prescribed breast and boost doses compared with 3D-conformal dose-planning. The mean lung
dose, the volume of the lungs receiving > 20 Gy, the mean heart dose, and volume of the heart
receiving > 30 Gy were significantly less with conventional treatment plans. Specific areas within
the breast and boost PTVs systematically received a lower than intended dose with conventional
treatment plans.
Conclusion: The shift towards CT-guided target definition and planning as the golden standard for
breast conserving radiotherapy has resulted in improved target coverage at the cost of larger
irradiated volumes and an increased dose delivered to organs at risk. Tissue is now included into
the breast and boost target volumes that was never explicitly defined or included with conventional
treatment. Therefore, a coherent definition of the breast and boost target volumes is needed,
based on clinical data confirming tumour control probability and normal tissue complication
probability with the use of 3D-conformal radiotherapy.
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Ever since the early days of breast cancer radiotherapy,
irradiation was performed by means of tangential beams
directed to treat the whole breast or chest wall [1]. With
the use of tangential beams, non-target thoracic structures
were avoided as much as possible. To ensure that all breast
parenchyma was included into the target volume, one
relied upon visible or palpable anatomy as assessed by
physical examination and/or fluoroscopy [2]. Standard
field borders were usually placed within a certain range
outside the palpable breast, while field projections and
collimator angles were verified and adapted by means of
radiographic examination. To enable computed dose cal-
culation and optimisation of wedge-fractions, one or
more body-outline contours were provided on which
dose-planning, with or without lung-density correction,
was performed [3]. However, the breast clinical target vol-
ume (CTV), i.e. the glandular breast tissue, was never
explicitly defined. Currently, breast cancer radiotherapy
has gradually shifted towards computed tomography
(CT)-guided treatment planning. This enabled the appli-
cation of new techniques such as three-dimensional (3D)-
conformal radiotherapy (3D-CRT) and intensity modu-
lated radiotherapy (IMRT) [4,5]. With these techniques,
an accurate delineation of the target volume is critical
because its size and shape directly affects the amount of
normal tissue irradiated. However, with regard to the def-
inition of the breast CTV, there is still no general consen-
sus, and target volume delineation is subject to a large
interobserver variability [6,7]. This may be explained by
the fact that it can be difficult to distinguish the glandular
breast tissue from the surrounding fatty tissue. In an effort
to solve this problem, the palpable breast is often marked
with a radiopaque wire during the CT scan [6]. The breast
CTV is then defined within the CT images, guided by this
radiopaque wire. Subsequently, a planning target volume
(PTV) can be defined and 3D-conformal breast beams can
be constructed. It appeared that large discrepancies exist
between a CT-guided beam set-up and beams defined dur-
ing the conventional process of direct simulation [8].
The introduction of CT-guided treatment planning also
seems to have influenced the way the lumpectomy cavity
with corresponding CTV and PTV are defined [9]. Nowa-
days, surgical clips, hematoma, seroma and other surgical
changes are used to define the target volume in 3D, while
in the conventional setting, information was limited to
the location of the scar and, when available, the position
of surgical clips.
Although several investigators drew attention to the volu-
metric and geometric changes introduced with CT-guided
treatment planning in breast conserving radiotherapy, the
dosimetric consequences, i.e. target coverage and dose
delivered to normal tissues, have not been clearly
assessed. Therefore, the purpose of this study was to com-
pare coverage of CT-based breast and boost planning tar-
get volumes (PTV), absolute volumes irradiated, and dose
delivered to the organs at risk with conventional treat-
ment plans and 3D-conformal breast conserving radio-
therapy.
Methods
Patients and CT scanning
Twenty-five patients with early-stage left-sided breast can-
cer that underwent radiotherapy after breast-conserving
surgery were included in this study. A planning CT scan in
treatment position was made for each patient. Before the
CT scan, skin marks were placed to locate the boost-vol-
ume isocenter and enable patient repositioning during
treatment. Radiopaque wires and markers were placed to
locate palpable breasts, scars, and skin marks on the CT
images. In addition, markers were placed to represent the
conventional field borders (i.e. a mid-sternal marker, rep-
resenting the medial field border, and a marker placed
20–30 mm dorsally from the lateral palpable breast repre-
senting the lateral field border). The cranial and caudal
field borders were marked 15 mm beyond the palpable
breast. Patients were scanned with CT from the level of the
larynx to the level of the upper abdomen, including both
lungs, with a scan thickness and index of 5 mm. The CT
data for all patients were transferred to the Helax-TMS 3D
treatment planning system, version 6.1B (Nucletron,
Veenendaal, The Netherlands). All patients provided
informed consent before starting therapy, and the ethics
committee at the University Medical Center Groningen
approved the procedures followed.
Reconstruction of conventional treatment plans
The markers representing the conventional field borders
were used to construct two opposing tangential beams by
means of virtual simulation, similar to the conventional
procedure by direct simulation as performed in the past at
our department. Wedge fractions were defined by evaluat-
ing dose distributions limited to a slice situated in the cen-
tre of the breast, and slices at 50 mm superior and inferior
to this central slice.
To enable definition of a conventional boost PTV (PTV-
CON), a body-outline contour of the slice containing the
boost-volume isocenter was derived from the CT data set.
All density information was erased. The body-outline con-
tour only contained the boost-volume isocenter, a two
dimensional (2D) reconstruction of all surgical clips, and
the marked location of the scar. On the basis of the posi-
tion of the clips and the available pre-operative informa-
tion, the assumed lumpectomy cavity was defined within
the 2D body-outline contour. Subsequently, the conven-
tional boost CTV (CTVCON) and the boost PTVCON were
created by adding margins of 10 mm and 5 mm, respec-Page 2 of 8
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into the CT data-set. The field length of the boost beams
was prescribed on the basis of the surgical clips, as visual-
ised by means of digitally reconstructed radiographs. The
conventional boost plan consisted of three equally
weighted photon beams with manually optimised gantry
angles. Beam widths and wedge fractions were selected in
such a way that the 95%-isodose closely encompassed the
boost PTVCON in the boost central slice. Dose distributions
in slices other than the boost central slice were not evalu-
ated and no additional shielding was used. For all beams
6-MV photons were used, and an energy fluence based
pencil beam algorithm was used for all dose calculations.
Eventually, a cumulative dose plan was calculated, taking
into account 50 Gy for the breast plan and an additional
16 Gy for the boost plan.
CT-guided definition of target volumes and organs at risk
The breast CT-based CTV (CTVCT) included the glandular
breast tissue of the ipsilateral breast. In practice, the breast
CTVCT was delineated within the extent of the radiopaque
wires marking the palpable breast. The breast CTVCT did
not extend into the pectoralis major or the ribs and did
not include the skin. The breast CT-based PTV (PTVCT)
was generated by adding a 3D-margin of 5 mm around
the breast CTVCT. Definition of the lumpectomy cavity
was guided by the position of the surgical clips and pre-
operative information, but also by hematoma, seroma,
and/or other surgery-induced changes, that were consid-
ered to be part of the lumpectomy cavity. The boost CTVCT
was generated by adding a 3D-margin of 10 mm around
the lumpectomy cavity. The boost PTVCT was generated
accordingly by adding an additional margin of 5 mm.
Both breast and boost PTVCT were restricted to 5 mm
within the skin surface. The heart was contoured to the
level of the pulmonary trunk superiorly, including the
pericardium, excluding the major vessels. Both lungs were
contoured as a single organ at risk with the automatic con-
touring tool of the Helax-TMS planning system, and the
right breast was contoured as an organ at risk similar to
the left breast CTVCT.
3D-conformal treatment planning
Conformal to the breast PTVCT, two opposing tangential
beams were constructed. With the use of beam's-eye-view
projections, gantry angles were determined to achieve
maximum avoidance of the heart, ipsilateral lung and
right breast. Shielding was adapted with use of a multileaf
collimator (MLC). Wedges and/or a maximum of three
MLC segments were added by means of forward planning
to obtain a homogeneous dose distribution. Subse-
quently, a boost plan was created conformal to the boost
PTVCT. It consisted of three equally weighted photon
beams with gantry angles identical to those that were used
with the conventional boost plan. Wedges and MLC
shielding were applied in such a way that the 95%-isodose
closely encompassed the boost PTVCT in three dimen-
sions, and a uniform dose distribution was obtained.
Eventually, a cumulative dose plan was calculated incor-
porating both the 3D-conformal breast and boost plan,
taking into account 50 Gy for the breast plan and an addi-
tional 16 Gy for the boost plan.
Analyses of target coverage and normal tissue dose
Target coverage was determined for both the conventional
and 3D-conformal dose plans by evaluating the relative
volumes of the breast PTVCT and the boost PTVCT receiving
at least 95% of the prescribed dose (i.e. the CT-guided
PTVs were regarded as the golden standard). For each of
the cumulative dose plans, the total volume and the vol-
ume outside the CT-based PTVs receiving at least 95% of
the prescribed breast and boost doses were determined. In
addition, the relative volumes of the heart receiving ≥ 30
Gy (V30), the mean heart dose, the relative total volume
of both lungs receiving ≥ 20 Gy (V20), the mean lung
dose, the relative volume of the right breast receiving ≥ 10
Gy (V10) and the right breast mean dose were derived
from the dose-volume histograms (DVH).
Statistical analysis
For comparison of the DVH parameters of the cumulative
dose plans, the mean values were analysed with the Wil-
coxon signed ranks test or the paired-samples t-test on sta-
tistical significance whenever appropriate. All tests were
two-tailed, and differences were considered statistically
significant at p ≤ 0.05.
Results
PTVCT coverage and absolute volumes irradiated
With conventional breast beams, coverage of the breast
PTVCT was adequate in 72% of the patients (in these
patients, ≥ 95% of the prescribed breast dose was deliv-
ered to ≥ 95% of the breast PTVCT). With 3D-CRT, cover-
age of the breast PTVCT was adequate for all patients
(Table 1). The volume outside the breast PTVCT that
received ≥ 95% of the prescribed breast dose was signifi-
cantly smaller when conventional breast beams were used
(427 cm3 vs. 529 cm3 with 3D-CRT).
With conventional boost beams, coverage of the boost
PTVCT was adequate in only 32% of the patients, while
coverage was adequate for all patients with 3D-CRT. The
volume outside the boost PTVCT that received ≥ 95% of
the prescribed boost dose was significantly less when con-
ventional beams were used (82 cm3 vs. 124 cm3 with 3D-
CRT).Page 3 of 8
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The mean heart dose and the heart V5–V30 were signifi-
cantly larger with the use of 3D-CRT (Table 2). Similar
results were observed with regard to the mean lung dose
and the lung V5–V30. The right breast mean dose and
right breast V5–V30 were minimal and similar for the 3D-
CRT and conventional cumulative dose plans.
Conventional field borders in relation to PTVCT
Conventional breast beams resulted in poor coverage of
the medio-dorsal and latero-dorsal areas of the breast
PTVCT in the majority of the patients (Fig. 1). Particularly
the latero-dorsal areas of the breast PTVCT significantly
extended beyond conventional field borders (Table 3).
The boost PTVCT generally extended beyond the boost
PTVCON in the medial and lateral directions (Fig. 2) and
Table 3). In the ventral and dorsal directions, the PTVCT
and PTVCON were mutually divergent in most cases, how-
ever no significant differences were found. The cranial and
caudal borders of the 3D-CRT boost beams extended
beyond the conventional boost beams in the majority of
patients.
Discussion
On the basis of the current analysis we conclude that CT-
guided target definition and planning for breast conserv-
ing radiotherapy results in improved target coverage at the
cost of an increased dose delivered to organs at risk. It
seems that when CT densities are used to define the breast
CTV, tissue is included that would not have been specifi-
cally targeted with conventional breast beams. However,
it is uncertain whether or not the additional included tis-
sue is really breast tissue at risk.
Table 1: Target coverage and irradiated volumes
Cumulative dose plan CT-based Cumulative dose plan Conventional p-values
Target coverage (%)
Breast PTVCT ≥ 95% 99.2 (97.7 – 100.0) 95.3 (84.5 – 100.0) < 0.001
Boost PTVCT ≥ 95% 99.6 (98.0 – 100.0) 90.1 (70.3 – 100.0) < 0.001
Irradiated volumes (cm3)
Volume ≥ 95% * 50 Gy 1276 (461 – 2239) 1142 (518 – 1968) 0.01
Volume ≥ 95% * 66 Gy 241 (105 – 491) 187 (84 – 376) < 0.001
Excess volumes (cm3)
≥ 95% * 50 Gy outside breast PTVCT 529 (257–1114) 427 (143 – 857) 0.02≥ 95% * 66 Gy outside boost PTVCT 124 (65 – 260) 82 (31 – 144) < 0.001
PTV: planning target volume; PTVCT: computed tomography (CT)-based PTV.
Data presented as mean values, with ranges in parentheses
Table 2: Mean dose and percentage of volume of heart, lungs and right breast irradiated
Organs at Risk CT-based cumulative dose plan Conventional cumulative dose plan p-values
Heart
Volume ≥ 30 Gy (%) 3.6 (0.0 – 10.9) 1.4 (0.0 – 7.9) < 0.001
Volume ≥ 20 Gy (%) 5.1 (0.0 – 14.0) 1.9 (0.0 – 9.5) < 0.001
Volume ≥ 10 Gy (%) 9.0 (0.0 – 22.7) 4.9 (0.0 – 18.0) < 0.001
Volume ≥ 5 Gy (%) 27.4 (9.5 – 57.4) 20.5 (0.0 – 47.7) < 0.001
Mean dose (Gy) 5.5 (2.5 – 10.8) 4.0 (1.4 – 9.0) < 0.001
Lungs
Volume ≥ 30 Gy (%) 4.7 (1.2 – 10.1) 3.5 (0.0 – 9.1) 0.014
Volume ≥ 20 Gy (%) 5.6 (1.7 – 11.1) 4.2 (0.2 – 10.2) 0.006
Volume ≥ 10 Gy (%) 8.2 (2.6 – 14.2) 6.7 (2.5 – 14.1) 0.010
Volume ≥ 5 Gy (%) 16.6 (5.2 – 28.1) 14.7 (7.3 – 26.6) 0.006
Mean dose (Gy) 4.7 (2.0 – 8.4) 4.0 (2.1 – 7.4) 0.011
Right breast
Volume ≥ 30 Gy (%) 0.1 (0.0 – 0.9) 0.0 (0.0 – 0.0) ns
Volume ≥ 20 Gy (%) 0.2 (0.0 – 2.9) 0.0 (0.0 – 0.0) ns
Volume ≥ 10 Gy (%) 0.3 (0.0 – 4.7) 0.0 (0.0 – 0.2) ns
Volume ≥ 5 Gy (%) 0.8 (0.0 – 7.8) 0.2 (0.0 – 1.8) ns
Mean dose (Gy) 0.9 (0.3 – 2.7) 0.9 (0.5 – 1.7) ns
Data presented as mean values, with ranges in parenthesesPage 4 of 8
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institutional guidelines used for delineation of the breast
target volumes. Various methods have been used in the
past to delineate the breast CTV: anatomic references have
been used as a guide [10,11], but also radiopaque wires
marking the palpable breast [6,12]. In some studies, a
conventional beam set-up was used even when CT data
were available [13,14]. In these studies, CT data were used
for dose calculation and evaluation of the dose to organs
at risk, while the breast CTV was not explicitly defined. In
addition, no margins for position uncertainties or penum-
bra were specified, while in other studies, a 5–7 mm mar-
gin for position uncertainties was used together with a
margin for penumbra [12,15]. This illustrates that consen-
sus is needed on how the breast target volumes should be
defined within the CT images. The delineation method
used in the present study, resulted in relatively consistent
results because the information used was threefold: 1)
palpable breast tissue marked by a radiopaque wire; 2)
glandular breast tissue as visible in the CT images; and 3)
the use of anatomic references. Therefore, we consider this
method to be the current golden standard for CT-guided
target definition in breast conserving RT.
Patient selection was started more than one year after the
introduction of CT-guided target definition and planning
as standard procedure for breast conserving RT at our
institution. Therefore, all involved physicians had at least
one year of experience, while there were regular interob-
server consultations to discuss the delineation of the tar-
get volumes. In this way, the effect of a learning curve was
eliminated as much as possible.
In the present study, the tangential beams of the conven-
tional and 3D-CRT plans were not adjusted when they
included more normal tissue than expected. However, in
our clinical practice, the gantry angles of the tangential
beams are adjusted when the contralateral breast is par-
tially included or when the central lung distance exceeds
30 mm. In some patients, avoidance of the contralateral
breast is not possible without a significant increase of the
dose delivered to the lungs. In these cases, inadequate cov-
erage of the medial and lateral aspects of the breast PTV is
accepted as long as adequate coverage of the boost PTV is
maintained.
Table 3: PTV volumes and dimensions
CT-based target definition Conventional target definition p-values
Absolute volumes (cm3)
Breast PTV 753 (209 – 1548) - -
Boost PTV 117 (40 – 243) - -
Breast PTVCT beyond conventional field borders (cm)
Medial 0.03 (-1.5 – 1.1) ns
Lateral 0.37 (-1.1 – 1.2) 0.01
Dimensions boost fields and PTVs (cm)
Field length 7.9 (5.4 – 10.4) 6.7 (4.5 – 8.5) < 0.001
PTVCT extending beyond PTVCON
right 0.18 (-0.6 – 1.2) 0.03
left 0.36 (-0.4 – 1.7) 0.01
ventral 0.22 (-1.7 – 1.7) ns
dorsal 0.23 (-0.7 – 2.5) ns
PTV: planning target volume; PTVCT: computed tomography (CT)-based PTV; PTVCON: conventional PTV. Data presented as mean values, with 
ranges in parentheses.
Dose-distribution conventional breast beams relative to CT-based breast target volumesFigure 1
Dose-distribution conventional breast beams relative 
to CT-based breast target volumes. Representation of 
95%-isodose (green) resulting from conventional breast 
beams and computed tomography (CT)-based clinical target 
volume (CTV) and planning target volume (PTV). Note the 
areas of PTV (red) not covered by 95%-isodose when con-
ventional beams are used. Under-dosage of PTV is caused by 
including additional tissue (marked yellow-wash areas) into 
the CTV.Page 5 of 8
(page number not for citation purposes)
Radiation Oncology 2008, 3:6 http://www.ro-journal.com/content/3/1/6The position of the conventional breast beams was evalu-
ated in relation to the breast PTVCT. Although 3D-CRT
field sizes were predominantly larger than conventional
field sizes, in some cases the resulting 3D-CRT fields were
actually smaller than the conventional fields. As shown in
Table 3, the medial aspect of the breast PTVCT was in some
cases positioned as far as 1.5 cm within the conventional
field borders, while the lateral aspect of the breast PTVCT
was in some cases positioned as far as 1.1 cm within the
conventional field borders.
In the present study, CT-guided target definition and plan-
ning resulted in larger boost PTVs that were inadequately
covered in 68% of the cases when conventional boost
beams were used. Although the volume increase can be
partly explained by the additional density information
provided by CT, it also appeared that with CT-guided
planning, the margins for penumbra needed in the cranial
and caudal directions could measure up to 10 mm. We
conclude that margins for position uncertainties and
penumbra were not fully taken into account when the
field lengths were prescribed for the conventional boost
beams.
In most cases, the boost PTVCT extended beyond PTVCON,
resulting in larger boost volumes with 3D-CRT. In some
patients, however, the CT-based lumpectomy cavity was
defined to (marginally) exclude one or more of the surgi-
cal clips when these appeared remote from the lumpec-
tomy cavity. In these patients, the PTVCON extended
beyond the PTVCT in one or more directions.
Equally weighted boost beams were used in the current
study. In our clinical practice, the boost-beam weights are
optimized for each individual patient. However, the two
treatment methods had different optimum boost-beam
weights. For methodological reasons, optimisation of the
boost-beam weights was not performed separately for the
two treatments.
While photon beams were used for boost irradiation in
the present study, others reported on the dosimetric
results with an electron boost. It was demonstrated by
Benda et al. [16] that target coverage with electron beams,
determined without the use of CT data, resulted in very
poor target coverage (with on average only 51% of the CT-
guided boost PTV receiving 90% or more of the prescribed
dose). It is likely that such inadequate coverage of the
boost volume has also been the case in the "boost vs. no
boost" trial [17,18]. This trial showed that an additional
boost dose of 16 Gy, delivered with the use of conven-
tional photon or electron techniques, significantly
reduced the risk of a local recurrence. Because it has been
demonstrated that in most cases, local recurrences occur
close to the primary tumour site [19], it may be possible
that CT-guided target definition in conjunction with 3D-
conformal dose-planning will further reduce the risk of
local recurrence as the dose distribution to the lumpec-
tomy cavity is more adequate.
CT-guided target definition and planning resulted in
higher doses delivered to the heart and lungs because
larger tangential beams were needed to include the breast
Conventional and CT-based boost planning target volumeFigure 2
Conventional and CT-based boost planning target volume. Transversal (left) and sagittal (right) cross-sections of con-
ventional and computed tomography (CT)-based boost planning target volume (PTV).Page 6 of 8
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V30. Although the absolute increase in normal tissue dose
seems to be relatively small, clinical consequences can
never be ruled out and attempts should always be made to
minimise the dose delivered to organs at risk. A number
of studies pointed out that patients who received partial
irradiation of the heart had an increased risk of dying
from cardiac disease [20-22]. In these studies, conven-
tional radiotherapy techniques were used. The present
study demonstrates that the introduction of CT-guided
target definition and planning may result in an increase of
the dose delivered to the heart in some cases. Other
authors already reported on restricting the 3D-CRT field
edges in the vicinity of the heart and the application of
cardiac shielding to reduce the heart dose [23]. We also
tested this method at our institute in three patients that
had upper-quadrant tumour sites. It appeared that the
heart V30 could be reduced to 0% at the cost of reduced
coverage of the breast PTVCT (Table 4). Although the use
of cardiac shielding was not specifically analysed as a part
of the current study, it could be regarded as a first and
rather safe step towards partial breast irradiation in
selected patients who have early-stage disease at locations
remote from the heart. In this way, it may be possible to
reduce the heart dose with 3D-CRT even below the levels
resulting from conventional treatment. A large rand-
omized trial would be necessary to determine tumour
control probability and normal tissue complication prob-
ability with the different uses of 3D-conformal techniques
in breast conserving radiotherapy.
Conclusion
The shift towards CT-guided target definition and plan-
ning as the golden standard for breast conserving radio-
therapy has resulted in improved target coverage at the
cost of larger irradiated volumes and an increased dose
delivered to organs at risk. Tissue is now included into the
breast and boost target volumes that was never explicitly
defined or included with conventional treatment. There-
fore, a coherent definition of the breast and boost target
volumes is needed, based on clinical data confirming
tumour control probability and normal tissue complica-
tion probability with the use of 3D-conformal radiother-
apy.
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